Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01506752
Other study ID # E2020-J081-034
Secondary ID
Status Completed
Phase Phase 1
First received January 6, 2012
Last updated June 25, 2012
Start date July 2011
Est. completion date September 2011

Study information

Verified date January 2012
Source Eisai Inc.
Contact n/a
Is FDA regulated No
Health authority Japan: Ministry of Health, Labor and Welfare
Study type Interventional

Clinical Trial Summary

The purpose of this study is to investigate the bioequivalence of improved and current orally disintegrating E2020 10 mg tablets as a single dose in Japanese healthy adult males for each of two administration methods (with/without water).


Recruitment information / eligibility

Status Completed
Enrollment 20
Est. completion date September 2011
Est. primary completion date September 2011
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Male
Age group 20 Years to 44 Years
Eligibility Inclusion Criteria

Those who meet all below criteria are eligible to enroll in this study;

1. Those who provide consent by their own will.

2. Male subjects aged between = 20 years and < 45 years old at the time of obtaining informed consent and non-smoker (subjects who have not been smoking for at least 4 weeks prior to study treatment)

3. BMI at screening is 18.5 kg/m2 or above and less than 25.0 kg/m2

4. Those who are willing to and can comply with the conditions described in the study protocol.

Exclusion Criteria

Those who meet any of the below criteria will be excluded from the study.

1. Any significant medical illness that required intervention within 8 weeks before treatment, or any medical history of clinically significant infectious diseases within 4 weeks before treatment.

2. Those who had any psychiatric, GI tract, hepatic, renal, respiratory, endocrine, hematological, neurological, cardiovascular diseases or congenital metabolic disorders within 4 weeks before study drug administration that may have an impact on the evaluation of the drug.

3. Subjects who have any medical history of GI, hepatic, or renal surgery (e.g. excision of liver, kidney or GI tract) that may have an impact on pharmacokinetics of the drug.

4. Subjects who have any history of medically significant allergy to medications or foods, and those who currently have any symptoms of seasonal

5. Subjects whose weight changes were more than 10% from the screening phase to study drug administration.

6. Those with clinical abnormal symptoms, medical history of organ dysfunction, subjective symptoms, objective findings, vital signs, and abnormal EKG or clinical laboratory test values, which need medical intervention.

7. Corrected change in QT wave (QTc) interval of > 450 msec with 12-lead EKG at screening or study drug administration.

8. Subjects who are positive for hepatitis B surface antigen (HBs antigen), hepatitis C (HCV) antibody, or serologic test for syphilis (STS).

9. Subjects who are suspected with or who has a history of drug or alcohol abuse, or positive urine screen for drugs of abuse or exhalation alcohol test at screening or baseline.

10. Subjects who consumed caffeine-containing food or beverages within 72 hours before study drug administration.

11. Exposure to any supplements or herbs (including Chinese medicine), or beverages (e.g. alcohol or grapefruit-containing beverages, within 2 weeks of study drug administration.

12. Exposure to St. John's wort containing medications within 4 weeks of study drug administration.

13. Use of any prescription drugs within 4 week before study drug administration.

14. Use of any OTC medications within 2 week before study drug administration.

15. Subjects who enrolled in another clinical trial and exposed to any investigational drug within 16 weeks of study enrollment.

16. Subjects who received blood infusion within 12 weeks, those who had blood drawn 400 mL or more within 12 weeks, 400 mL, or 200 mL or more within 4 weeks, or sampling of a component of the blood within 2 week of study drug administration.

17. Subjects who performed extreme exercises or exhausting labors (more than 1 hr/day or 5 day/week) within 2 weeks before hospitalization.

18. Any subject who, or whose partner, does not want to take highly reliable contraceptive measures until the end of the post-treatment examination.

19. Subjects who are inappropriate to participate in the study, as judged by the investigator or subinvestigator

Study Design

Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label


Related Conditions & MeSH terms


Intervention

Drug:
Donepezil Hydrochloride
improved orally disintegrating E2020 10 mg tablet without water.
Donepezil Hydrochloride
current orally disintegrating E2020 10 mg tablet without water.
Donepezil Hydrochloride
improved orally disintegrating E2020 10 mg tablet with water.
Donepezil Hydrochloride
current orally disintegrating E2020 10 mg tablet with water

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Eisai Co., Ltd.

Country where clinical trial is conducted

Japan, 

Outcome

Type Measure Description Time frame Safety issue
Primary PK Parameter Cmax, calculated from plasma E2020 concentration by a non-compartmental analysis, will be evaluated. Up to 168 hrs after administration No
Primary PK Parameter AUC(0-168), calculated from plasma E2020 concentration by a non-compartmental analysis, will be evaluated. Up to 168 hrs after administration No
See also
  Status Clinical Trial Phase
Completed NCT02257151 - Study to Evaluate the Safety, Pharmacokinetics and Target Engagement of BMS-986142 in Healthy Subjects Phase 1
Completed NCT06169059 - To Evaluate the Safety and Pharmacokinetic Characteristics After Multiple Administration of JC-013 and JLP-2004 Phase 1
Completed NCT06165965 - To Evaluate the Safety and Pharmacokinetic Characteristics After the Administration of JT-001, JT-002 and JLP-2008 Phase 1
Completed NCT06401915 - Intelligent Assistive Technologies for Dementia
Completed NCT01506739 - A Bioequivalence Study of Film-coated Tablet and Dry Syrup 1% Form for E2020 in Healthy Japanese Adult Males Phase 1
Completed NCT00400309 - Safety of REPEVAX® Given One Month After REVAXIS® Phase 3
Completed NCT04027218 - Clinical Trial to Assess the Effectiveness of Applying Dry Local Heat and/ or High Tourniquet Pressure for Venipuncture. N/A
Completed NCT05408572 - Study of SON-1010 (IL12-FHAB) in Healthy Adults Early Phase 1
Not yet recruiting NCT04964245 - Respiratory Measurement of Volume Change Using Accelerometer, Thermographic Camera Electrical Impedance Tomography and Motion Correlation Analysis Using Mattress Sensor in Healthy Individuals N/A
Completed NCT03827005 - L-arginine Supplementation and Resistance Exercise N/A
Completed NCT05688566 - Biomechanical Characteristics of Lower Extremity During Pinnacle Trainer With Different Pedal Angles N/A
Completed NCT06171880 - To Evaluate the Safety and Pharmacokinetic Characteristics After the Administration of JC-001 and JLP-1901 Phase 1
Completed NCT01274130 - Investigatory Study of Metformin's Pharmacokinetics, Pharmacodynamics and Drug Drug Interactions Classifying the Group by MATE1 Genotype in Healthy Volunteers N/A
Withdrawn NCT04762823 - Multiple Sessions of Transcranial Direct Current Stimulation in People With Parkinson's Disease N/A
Recruiting NCT06385639 - Efficacy and Safety of Probiotic Products for Digestive Health N/A
Not yet recruiting NCT06344533 - Study of JMKX003142 Injection in Chinese Healthy Subjects Phase 1